AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
- OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company's Q2 2023 operational and financial results on Tuesday, August 15, 2023 at 8:30 AM ET.
- 08/09/2023
|
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
- OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K Equels, M.S.
- 06/14/2023
|
AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast
- OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — announced today that management will host a conference call and webcast to discuss the Company's Q1 2023 operational and financial results on Tuesday, May 16, 2023 at 8:30 AM ET.
- 05/09/2023
|
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
- OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced that it will report its financial results for the full year December 31, 2022 after market close on Friday, March 31, 2023. AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3rd at 8:30 AM ET.
- 03/27/2023
|
AIM ImmunoTech shares rise on news of pancreatic cancer research partnership with AstraZeneca and Erasmus Medical Center
- AIM ImmunoTech Inc (NYSE:AIM) (AIM) announced that it has entered into an external sponsored collaborative clinical research agreement with AstraZeneca and Erasmus Medical Center in the Netherlands that will evaluate the potential of AIM's Ampligen (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab) for the treatment of pancreatic cancer. Ampligen is AIM's dsRNA drug currently being developed for globally important cancers.
- 01/17/2023
|
5 Penny Stocks To Watch After Big News This Week
- Penny stocks to watch with news that are turning heads in the stock market this week. The post 5 Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/17/2023
|
AIM ImmunoTech broadens patent portfolio with new Netherlands utility patent
- AIM ImmunoTech Inc (NYSE:AIM) has announced that the Netherlands Patent Office has granted the company a utility patent covering rugged dsRNA, a double-stranded RNA product related to its lead candidate Ampligen (rintatolimod), which claims cover, among other aspects, compositions, and compositions for use in the prevention or treatment of COVID-19. The new patent broadens AIM's existing portfolio for COVID-19 treatments to include rugged dsRNA, the company said.
- 01/09/2023
|
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event'
- Live video webcast on Wednesday, January 18th at 11:00 AM ET Live video webcast on Wednesday, January 18th at 11:00 AM ET
- 01/05/2023
|
AIM ImmunoTech promotes Christopher McAleer to the role of scientific officer
- AIM ImmunoTech Inc (NYSE:AIM) has announced the promotion of Christopher McAleer from the company's deputy scientific officer to the position of scientific officer. The immuno-pharma firm said McAleer is an accomplished scientist with a diverse range of skills from general wet lab technique to company-wide operations management.
- 12/12/2022
|
AIM ImmunoTech reports positive safety, tolerability, and biological activity data from Phase 1 Ampligen study
- AIM ImmunoTech Inc (NYSE:AIM) has reported positive safety, tolerability, and biological activity data from a Phase 1 study involving the intranasal administration of its lead product Ampligen (rintatolimod) in healthy subjects. Ampligen is an immuno-modulator with broad-spectrum activity being developed by AIM for globally important cancers, viral diseases and disorders of the immune system.
- 12/08/2022
|
AIM ImmunoTech says cash position expected to fund operations through end of 2023
- AIM ImmunoTech Inc (NYSE:AIM) said it ended the third quarter of 2022 with cash and cash equivalents of $36.7 million, down from $48.3 million at the end of December 2021, but expected to fund operations through to the end of 2023. The Ocala, Florida-based company said research and development expenses for the three months ended September 30, 2022, were $1.4 million, compared to $2 million for the same period in 2021.
- 11/15/2022
|
AIM ImmunoTech shows positive results using Ampligen in treating triple negative breast cancer
- AIM ImmunoTech Inc (NYSE:AIM) has revealed positive data evaluating Ampligen (rintatolimod) as a component of a regimen for the treatment of early-stage triple negative breast cancer. Led by by Roswell Park Comprehensive Cancer Center medical oncologist Dr Shipra Gandhi, the data will be presented in a poster presentation at the Society for Immunotherapy of Cancer 37th annual meeting being held virtually and in Boston, Massachusetts from November 8 to 12, 2022.
- 11/14/2022
|
Aimia: Trading Close To Net Cash + Marketable Securities With M&A Optionality
- Aimia is trading approximately around its net cash plus marketable securities value. Applying punitive discounts to its private investments, Aimia's NAVPS is roughly 30% above where the stock is trading.
- 11/13/2022
|
Aimia, Inc. (AIMFF) Q3 2022 Earnings Call Transcript
- Aimia, Inc. (OTCPK:AIMFF) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Albert Matousek - Head, IR & Communications Phil Mittleman - CEO Michael Lehmann - President Steve Leonard - CFO Conference Call Participants Surinder Thind - Jefferies Brian Morrison - TD Securities Operator Good morning, ladies and gentlemen, and welcome to the Aimia, Inc. Third Quarter 2022 Results Conference Call. At this time, all lines are in listen-only mode and following the presentation we will conduct a question-and-answer session.
- 11/09/2022
|
AIM ImmunoTech to add board members, review executive salaries; highlights clinical advances in past year
- AIM ImmunoTech Inc (NYSE:AIM) said it will add two directors to its board to bring diversity and additional biotechnology commercialization experience. AIM ImmunoTech also said its board compensation committee will engage an independent compensation consultant to evaluate the compensation plans currently in place for company executives.
- 11/09/2022
|
AIM ImmunoTech's product candidate Ampligen granted FDA Orphan Drug Designation for treatment of Ebola
- AIM ImmunoTech Inc (NYSE:AIM) announced that its dsRNA product candidate Ampligen (rintatolimod) has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of Ebola virus disease. The company said it was developing Ampligen for globally important cancers, viral diseases, and disorders of the immune system.
- 11/02/2022
|
AIM ImmunoTech backed by Delaware Court of Chancery's decision to deny activist group's takeover bid
- AIM ImmunoTech Inc (NYSE:AIM) said the Delaware Court of Chancery has denied an activist investor's bid to put two nominees on its board during the November 3 annual meeting of shareholders. In its decision, the court denied Jonathan Jorgl's motion for a mandatory preliminary injunction that sought to require the AIM board of directors to accept his director nominations and include his nominees on a universal proxy card.
- 10/31/2022
|
AIM ImmunoTech receives regulatory go-ahead for Phase 2 trial of investigational drug Ampligen for patients with post-COVID conditions
- AIM ImmunoTech Inc (NYSE:AIM) told investors it expects to begin enrolling patients in the first quarter next year for a Phase 2 trial of its investigational drug Ampligen as a therapeutic for patients with post-COVID conditions following regulatory approval. The US Food and Drug Administration (FDA) have cleared the firm's Investigational New Drug (IND) application for the drug AMP-518.
- 10/12/2022
|
AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
- Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra Internal Medicine on Wednesday, September 28th at 3:00 PM ET Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra Internal Medicine on Wednesday, September 28th at 3:00 PM ET
- 09/21/2022
|
AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- OCALA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D. Chief Executive Officer of AIM, will present at the virtual H.C. Wainwright 24 th Annual Global Investment Conference being held in New York, N.Y., and virtually, September 12-14, 2022.
- 09/07/2022
|
AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
- OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced Chris McAleer, Ph.D., Deputy Chief Science Officer of AIM, and William Mitchell, M.D. Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022. In addition to management's presentations, the Company is proud to announce its sponsorship of the event.
- 09/06/2022
|
AIM ImmunoTech says study partner Roswell Park begins patient enrollment in Ampligen and resistant melanoma phase 2 trial
- AIM ImmunoTech Inc (NYSE:AIM) said its clinical development collaborator Roswell Park Comprehensive Cancer Center has commenced patient enrollment in its phase 2 study evaluating Ampligen (rintatolimod) in subjects with primary PD-1/PD-L1 resistant melanoma. The company said the study, which is funded by the National Cancer Institute (NCI), will evaluate type-1 polarized dendritic cell (αDC1) vaccine in combination with tumor-selective chemokine modulation comprised of Interferon alpha 2b, Ampligen, and Celecoxib.
- 08/30/2022
|
AIM ImmunoTech gets Institutional Review Board approval to begin Phase 2 pancreatic cancer trial of Ampligen
- AIM ImmunoTech Inc (NYSE:AIM) announced that its Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (LAPC) has commenced after its trial protocol received approval from an Institutional Review Board (IRB). The company's Phase 2 study Investigational New Drug (IND) application for Ampligen was previously cleared by the US Food and Drug Administration (FDA).
- 08/18/2022
|
AIM ImmunoTech ends 2Q well-positioned to achieve multiple clinical and regulatory milestones
- AIM ImmunoTech Inc (NYSE:AIM) posted second-quarter financial results that showed ample cash on hand, giving the company scope to achieve multiple clinical and regulatory milestones. The Florida-based company's lead candidate Ampligen (rintatolimod), an immuno-modulator with broad spectrum activity, is being developed to treat multiple types of cancers, immune disorders, and viral disorders, including coronavirus (COVID-19).
- 08/15/2022
|
Aimia, Inc. (AIMFF) CEO Philip Mittleman on Q2 2022 Results - Earnings Call Transcript
- Aimia, Inc. (OTCPK:AIMFF) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Steven Leonard - CFO Philip Mittleman - CEO & Director Michael Lehmann - President & Director Conference Call Participants Brian Morrison - TD Securities Operator Good morning, ladies and gentlemen, and welcome to the Aimia Inc. Second Quarter 2022 Results Conference Call. [Operator Instructions].
- 08/12/2022
|
AIM ImmunoTech reveals positive pilot study data from EAP evaluating Ampligen for treatment of Long COVID
- AIM ImmunoTech Inc (NYSE:AIM) has announced what it calls positive preliminary pilot study data from its ongoing Expanded Access Program (EAP) evaluating its investigational drug Ampligen as a therapeutic for Long COVID. The immuno-pharma firm said the preliminary data from this uncontrolled clinical trial found that patients reported statistically significant improvements in chronic fatigue after treatment with Ampligen and, based on these early results, the company is working to move forward with a Phase 2 controlled trial.
- 07/28/2022
|
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series
- Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July 25th at 8:30 AM ET Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July 25th at 8:30 AM ET
- 07/14/2022
|
AIM ImmunoTech inks lease deal for new state-of-the-art product development and testing facility in New Jersey
- AIM ImmunoTech Inc (NYSE:AIM) announced that it has entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square foot research and development (R&D) facility at the state-supported New Jersey Bioscience Center (NJBC). The immuno-pharma company said the incubator at North Brunswick, New Jersey, which is designed for small businesses in the region, is dedicated to life sciences and biotechnology companies, and the NJBC has invested over $70 million in facilities and improvements to its campus.
- 06/21/2022
|
AIM ImmunoTech boosts intellectual property with new Netherlands utility patent covering Ampligen and dsRNA products aimed at COVID-19
- AIM ImmunoTech Inc (NYSE:AIM) revealed that the Netherlands Patent Office (Octrooicentrum Nederland) has issued Patent No 2027383 - a utility patent - covering Ampligen (rintatolimod) and other dsRNA products developed by the company for use in the prevention, or treatment of coronavirus (COVID-19), with a base patent term extending until 2041. The Ocala, Florida-based immuno-pharma company's RNA product candidate is being developed for globally important cancers, viral diseases and disorders of the immune system.
- 06/13/2022
|
AIM ImmunoTech to file Investigational New Drug application for Ampligen to treat long COVID
- AIM ImmunoTech Inc (NYSE:AIM) has announced that it is working towards filing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its long COVID investigational drug Ampligen, partly based on positive early data from its ongoing clinical trial. The company said it had amended its ongoing FDA-authorized AMP-511 trial to enroll four post-COVID patients with new onset myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) following acute COVID-19.
- 05/18/2022
|
AIM ImmunoTech says Ampligen data supports synergistic potential with checkpoint blockade therapies
- AIM ImmunoTech Inc (NYSE:AIM) has provided a summary of positive clinical data supporting the synergistic potential of its flagship drug Ampligen (rintatolimod) with checkpoint blockade therapies. In a statement, AIM ImmunoTech CEO Thomas Equels said: “We have amassed a growing body of encouraging Ampligen data to date through close collaborations with leading KOLs at preeminent institutions.
- 04/21/2022
|
AIM ImmunoTech engages CRO Amarex Clinical Research to manage Phase 2 of Ampligen study
- AIM ImmunoTech Inc (NYSE:AIM). has engaged Amarex Clinical Research LLC to manage the Phase 2 study of its flagship drug candidate Ampligen as a therapy for locally advanced pancreatic cancer (AMP-270), with clinical trial on track to start in the third quarter of this year.
- 04/12/2022
|
AIM ImmunoTech reports positive data from Phase 2a study evaluating Ampligen as part of a regimen treating colorectal cancer that has spread to the liver
- AIM ImmunoTech Inc (NYSE:AIM) presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evaluating its flagship drug Ampligen (rintatolimod) as a component of a Chemokine Modulatory (CKM) regimen for the treatment of colorectal cancer metastatic to the liver at the six-day annual meeting of the American Association for Cancer Research (AACR), which kicked off on April 8, in New Orleans, Louisiana. The Ocala, Florida-based immuno-pharma company said the research was led by Roswell Park medical oncologist Sarbajit Mukherjee, in collaboration with senior investigator Pawel Kalinski, who is the chair of I=immunology at Roswell Park.
- 04/11/2022
|
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
- What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/11/2022
|
AIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer Setting
- AIM ImmunoTech Inc (NYSE: AIM) has announced the presentation of positive data from a Phase 1 study of Ampligen in metastatic triple-negative breast cancer. The pre-determined primary efficacy endpoint was met (increase in CD8⍺ in TME).
- 04/11/2022
|
AIM ImmunoTech reports ‘strong' balance sheet to fund operations and clinical development programs through 2023
- AIM ImmunoTech Inc (NYSE:AIM) said it has a “strong” balance sheet that will fund operations and clinical development programs through 2023. In a statement reporting its financial results for 2021, the Florida-based company said it ended the year with cash and cash equivalents of $48.3 million as it advances its flagship drug candidate Ampligen (rintatolimod) to treat cancers, viral diseases and disorders of the immune system.
- 04/01/2022
|
AIM ImmunoTech says data from Ampligen study on pancreatic cancer accepted for presentation at upcoming IHPBA World Congress
- AIM ImmunoTech Inc (NYSE:AIM) said data from a study evaluating the direct effects of its flagship drug candidate Ampligen (rintatolimod) on human pancreatic ductal adenocarcinoma (PDAC) cells has been accepted for presentation at the upcoming 15th Annual International Hepato-Pancreato-Biliary Association (IHPBA) World Congress in New York City. “We are encouraged by the data demonstrated by Ampligen and its potential to offer beneficial anti-tumor effects in pancreatic cancer patients,” AIM ImmunoTech CEO Thomas Equels said in a statement.
- 03/28/2022
|
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
- The FDA has lifted the clinical hold on AIM ImmunoTech Inc's (NYSE: AIM) investigational new drug (IND) application for a Phase 2 study of Ampligen for locally advanced pancreatic cancer (AMP-270). The AMP-270 clinical trial's primary objective compares the efficacy of.
- 03/16/2022
|
AIM ImmunoTech wins IND clearance from FDA to proceed with Phase 2 study of Ampligen for treating locally advanced pancreatic cancer
- AIM ImmunoTech Inc (NYSE:AIM) revealed that it has received a notification from the US Food and Drug Administration (FDA) stating that the clinical hold on the company's investigational new drug (IND) application for a Phase 2 study of its flagship drug candidate Ampligen as a therapy for locally advanced pancreatic cancer (AMP-270) has been lifted. The Ocala, Florida-based immuno-pharma company said that it can now proceed with the study.
- 03/16/2022
|
AIM ImmunoTech announces appointment of Robert Dickey IV, as its chief financial officer
- AIM ImmunoTech Inc (NYSE:AIM) has announced the appointment of Robert Dickey IV, as its chief financial officer (CFO). Effective April 4, 2022, AIM ImmunoTech said, Dickey will become CFO and current CFO Ellen Lintal will transition to serve as a finance and accounting consultant for the company.
- 03/03/2022
|
AIM ImmunoTech announces positive results from Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
- AIM ImmunoTech Inc (NYSE:AIM) announced positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer. The study has been published in the American Association for Cancer Research publication, Clinical Cancer Research under the title, “Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity.
- 01/24/2022
|
AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference
- Live video webcast presentation on Wednesday, January 26th at 10:00 AM ET Live video webcast presentation on Wednesday, January 26th at 10:00 AM ET
- 01/19/2022
|
AIM ImmunoTech developing immuno-therapeutics to treat cancer and fight coronavirus
- Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of coronavirus Positive results from a pancreatic cancer Early Access Program (EAP) evaluating Ampligen in the Netherlands. What AIM ImmunoTech does: AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) is an immuno-pharma company headquartered in Ocala, Florida which is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders.
- 12/09/2021
|
AIM ImmunoTech's Ampligen safety data presented at Eighth European Scientific Working Group on Influenza
- AIM ImmunoTech Inc (NYSE:AIM) has announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria. The conference, which ran from December 4-7, 2021, also included research on coronavirus (COVID-19) and respiratory syncytial virus.
- 12/09/2021
|
AIM ImmunoTech CEO to Participate in Two Upcoming Investor Conferences
- OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming investor conferences.
- 12/06/2021
|
AIM ImmunoTech closes 3Q with $53.7M balance sheet
- AIM ImmunoTech Inc (NYSE:AIM) closed its third quarter with a $53.7 million balance sheet as the company advances Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. “We are proud of the progress made through the third quarter,” said CEO Thomas Equels in a statement.
- 11/16/2021
|
AIM ImmunoTech submits IND and Fast Track applications for Phase 2 trial of Ampligen pancreatic cancer therapy
- AIM ImmunoTech Inc said it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the US Food and Drug Administration (FDA) for a planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. The company said the planned AMP-270 clinical trial of around 250 subjects will be a randomized, open-label, controlled, parallel-arm study with the primary objective of comparing the efficacy of Ampligen when added to SOC (standard of care) versus SOC alone for subjects with advanced pancreatic carcinoma recently treated with FOLFIRINOX chemotherapy regimen.
- 10/19/2021
|
AIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer
- OCALA, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the U.S. Food and Drug Administration (FDA) for a planned Phase 2 study of the company's drug Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer.
- 10/19/2021
|
AIM ImmunoTech moving forward to develop Ampligen as intranasal coronavirus treatment as it publishes Phase I safety data
- AIM ImmunoTech Inc (NYSE:AIM) reported that a Phase 1 clinical study of Ampligen as an intranasal treatment for coronavirus (COVID-19) had shown "no severe adverse events" and that the drug was "generally well tolerated". The trial saw 40 healthy subjects receive either Ampligen or a placebo, with the Ampligen given at four escalating dosages across four cohorts, to a maximum level of 1,250 micrograms.
- 10/06/2021
|
AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy
- OCALA, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company's belief that its drug Ampligen has significant potential as an intranasal therapeutic for COVID-19.
- 10/06/2021
|
AIM ImmunoTech finalizes protocol for planned Phase 2 study of Ampligen in patients with pancreatic cancer
- AIM ImmunoTech Inc announced that it has finalized the protocol for a planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. The company expects to submit both an Investigational New Drug application (IND) and a request for Fast Track status with the US Food and Drug Administration (FDA) by no later than October 18.
- 10/04/2021
|
AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer
- Finalizes and reports Phase 2 study protocol
- 10/04/2021
|
AIM ImmunoTech developing immuno-therapeutics to treat cancer and fight coronavirus
- Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of coronavirus Positive results from a pancreatic cancer Early Access Program (EAP) evaluating Ampligen in the Netherlands. What AIM ImmunoTech does: AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) is an immuno-pharma company headquartered in Ocala, Florida which is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders.
- 10/04/2021
|
AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses
- AIM ImmunoTech Inc (NYSE: AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis against respiratory viruses. The HCT will test Ampligen as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2).
- 09/30/2021
|
AIM ImmunoTech inks clinical trial agreement for a Phase 2a Human Challenge Trial of Ampligen as an intranasal prophylaxis against respiratory viruses
- AIM ImmunoTech Inc. said it has signed a signed clinical trial agreement for a Phase 2a Human Challenge Trial (HCT) with hVIVO for a Phase 2a Human Challenge Trial (HCT) to test the company's flagship drug Ampligen as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2).
- 09/30/2021
|
AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses
- The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafter The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafter
- 09/30/2021
|
AIM ImmunoTech Plans To Evaluate Two Forms Of Ampligen In Early-COVID-19 Disease
- AIM ImmunoTech Inc (NYSE: AIM) submitted a Pre-Investigational New Drug Application (Pre-IND) to the FDA for COVID-19 trials with Ampligen. The application is for two separate Phase 2 clinical studies to study the potential of Ampligen as both an infusion and an intranasal therapy for early-onset COVID-19.
- 09/28/2021
|
AIM ImmunoTech submits Pre-IND application to FDA for Phase 2 trials of Ampligen as potential therapeutic for early-onset coronavirus
- AIM ImmunoTech Inc announced it had submitted a pre-investigational New Drug application (pre-IND) to the US Food and Drug Administration (FDA) for two separate Phase 2 clinical studies to study Ampligen as both an infusion and an intranasal therapy for early-onset coronavirus (COVID-19). "With Ampligen's recently established intranasal safety profile, and the preliminary results from these trials, we may be able to show that Ampligen not only has an early-onset therapeutic effect against a broad spectrum of respiratory viruses, but also may provide a boost to post-infection immunity that will confer cross-protection against viral variants," AIM CEO Thomas K.
- 09/28/2021
|
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19
- AIM Has Reached Multiple Major Milestones Demonstrating Strong Progress in Developing its COVID-19 Portfolio AIM Has Reached Multiple Major Milestones Demonstrating Strong Progress in Developing its COVID-19 Portfolio
- 09/28/2021
|
AIM ImmunoTech files provisional patent for Ampligen as a potential early-onset intranasal therapy
- AIM ImmunoTech Inc said it has submitted a provisional patent application for Ampligen as a potential early-onset intranasal therapy. This therapeutic use is designed to enhance and expand infection-induced immunity, epitope spreading, cross-reactivity and cross-protection in patients exposed to a wide range of RNA respiratory viruses, such as influenza, Rhinoviruses and SARS-CoV-2, which causes the coronavirus (COVID-19).
- 09/27/2021
|
AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses
- OCALA, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced the filing of a provisional patent application for Ampligen as a potential early-onset intranasal therapy designed to enhance and expand infection-induced immunity, epitope spreading, cross-reactivity and cross-protection in patients exposed to a wide range of RNA respiratory viruses, such as influenza, Rhinoviruses and SARS-CoV-2, which causes the disease COVID-19.
- 09/27/2021
|
AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients
- AIM ImmunoTech Inc (NYSE: AIM) has announced positive progress with the FDA meeting request concerning a Phase 2 study of Ampligen for Post-COVID-19 Cognitive Dysfunction (PCCD). The meeting request has been deemed sufficient for transfer to the FDA's Division of Neurology by the FDA's COVID Scientific Technical Triage Team.
- 09/21/2021
|
AIM ImmunoTech advances bid to study Ampligen as therapy for Post-COVID-19 Cognitive Dysfunction
- AIM ImmunoTech Inc has progressed a step further in its bid to get Ampligen into a clinical trial to test it as an infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD) - a new and serious coronavirus-induced disease for which there is currently no treatment. The FDA has deemed a meeting request sufficient for transfer now to the regulator's Division of Neurology by the FDA's Covid scientific technical triage team.
- 09/21/2021
|
AIM ImmunoTech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-COVID-19 Cognitive Dysfunction
- OCALA, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company's meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen as an infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD). The meeting request has been deemed sufficient for transfer to the FDA's Division of Neurology by the FDA's Covid Scientific Technical Triage Team.
- 09/21/2021
|
AIM ImmunoTech offers a status update on its pending Phase 2a Human Challenge Trial using its flagship drug Ampligen
- AIM ImmunoTech Inc. provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company's flagship drug Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus (HRV-16), which is a common cold virus, and influenza A virus (H3N2).
- 09/20/2021
|
AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen
- OCALA, Fla., Sept. 20, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company's drug Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2). The proposed protocol for the AIM-sponsored study was submitted to the Oxford Research Ethics Committee (REC)/Medicines and Healthcare Regulatory Agency (MHRA) on September 10, 2021. A meeting is scheduled to review the study on September 24, and the response is expected by mid November.
- 09/20/2021
|
AIM ImmunoTech To Test Ampligen In Post-COVID-19 Cognitive Dysfunction
- AIM ImmunoTech Inc (NYSE: AIM) has submitted a Pre-Investigational New Drug application (Pre-IND) to the FDA for a Phase 2 study of Ampligen as a potential infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD). The trial will evaluate the efficacy and safety of Ampligen in patients experiencing PCCD.
- 09/08/2021
|
AIM ImmunoTech submits pre-Investigational New Drug application to the US FDA for a Phase 2 clinical study of Ampligen as a potential infusion therapy for post-COVID-19 Cognitive Dysfunction
- AIM ImmunoTech Inc. said it has submitted a pre-Investigational New Drug (Pre-IND) application to the US Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a potential infusion therapy for post-coronavirus (COVID-19) Cognitive Dysfunction (PCCD).
- 09/08/2021
|
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction
- OCALA, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a potential infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD).
- 09/08/2021
|
AIM ImmunoTech files provisional patent application for use of Ampligen in Post-COVID-19 Cognitive Dysfunction
- AIM ImmunoTech Inc has announced a new provisional patent application for its flagship drug candidate Ampligen as both an intranasal and an intravenous therapy for what the company describes as Post-COVID-19 Cognitive Dysfunction (PCCD). The Ocala, Florida-based immuno-pharma company has been working steadily to expand its coronavirus (COVID-19) patent portfolio.
- 08/25/2021
|
AIM ImmunoTech is well positioned with $57.3M to advance clinical trials of flagship drug Ampligen
- AIM ImmunoTech Inc (NYSE:AIM) posted second-quarter results that demonstrated that it is in a strong financial position with $57.3 million to press ahead with clinical trials and execute on its corporate strategy. For the period ended June 30, 2021, the Ocala, Florida-based immuno-pharma company had cash, equivalents and marketable securities of $57.3 million, compared to $54.4 million as of December 31, 2020.
- 08/17/2021
|
AIM ImmunoTech is well positioned with $57.3M to advance clinical trials of Ampligen as cancer, coronavirus treatment
- AIM ImmunoTech Inc (NYSE:AIM) posted second-quarter results that demonstrated that it is in a strong financial position with $57.3 million to press ahead with clinical trials and execute on its corporate strategy. For the period ended June 30, 2021, the Ocala, Florida-based immuno-pharma company had cash, equivalents and marketable securities of $57.3 million, compared to $54.4 million as of December 31, 2020.
- 08/17/2021
|
AIM ImmunoTech is well positioned with $57.3M to execute on its corporate strategy and advance clinical trials
- AIM ImmunoTech Inc posted second-quarter results that demonstrated that it is in a strong financial position with $57.3 million to press ahead with clinical trials and execute on its corporate strategy. For the period ended June 30, 2021, the Ocala, Florida-based immuno-pharma company had cash, equivalents and marketable securities of $57.3 million, compared to $54.4 million as of December 31, 2020.
- 08/17/2021
|
AIM ImmunoTech Provides Second Quarter 2021 Business Update
- OCALA, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.
- 08/17/2021
|
AIM CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc.
- BioFlorida is the State's Leading Life Sciences Industry Association BioFlorida is the State's Leading Life Sciences Industry Association
- 08/16/2021
|
AIM ImmunoTech inks contract to sponsor Phase 2a trial to test Ampligen as a cold and flu therapy
- AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company's Ampligen drug as a potential intranasal antiviral therapy to treat Rhinovirus hRV (common cold virus) and Influenza. The company said a successful Phase 2a study could establish Ampligen as a potential prophylaxis against future viral variants and future novel respiratory viruses for which there are no current therapies, as well as known viruses such as SARS-CoV-2, which causes coronavirus (COVID-19).
- 07/09/2021
|
8 ‘Must Watch' Penny Stocks For Your July 2021 List
- Are these 'must watch' penny stocks on your radar? The post 8 ‘Must Watch' Penny Stocks For Your July 2021 List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/09/2021
|
AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy
- Subjects will be exposed under controlled clinical facilities and medical monitoring to A/Perth/16/2009 (H3N2) or human rhinovirus (hRV-16) to gauge Ampligen's effectiveness against those, and potentially other viruses Subjects will be exposed under controlled clinical facilities and medical monitoring to A/Perth/16/2009 (H3N2) or human rhinovirus (hRV-16) to gauge Ampligen's effectiveness against those, and potentially other viruses
- 07/09/2021
|
AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET
- OCALA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming milestones. Investors and other interested parties are invited to submit questions to management prior to the call's start via email to aim@crescendo-ir.com.
- 07/06/2021
|
AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen
- Company is Planning a Phase 2 Study of its Drug as a Broad-Spectrum Respiratory Virus Prophylaxis Company is Planning a Phase 2 Study of its Drug as a Broad-Spectrum Respiratory Virus Prophylaxis
- 06/21/2021
|
AIM ImmunoTech says Ampligen featured in medical journal as potential treatment for cancer patients infected with SARS-CoV-2
- AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) reports that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers as a potential treatment option for cancer patients infected with SARS-CoV-2. In a statement, the company said the study's authors stated that Ampligen has the potential to reduce the severity of the deadly respiratory disease COVID-19, which has so far caused more than 3.7 million deaths globally.
- 06/14/2021
|
AIM ImmunoTech's Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2
- The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade Inhibitors The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade Inhibitors
- 06/14/2021
|
AIM ImmunoTech extends pact with Shenzhen Smoore Technology to develop Ampligen as inhalation therapy for coronavirus, other respiratory diseases
- AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) has entered into a two-year agreement extension with Shenzhen Smoore Technology Limited (Smoore) with the goal of developing Ampligen as a potential inhalation therapy for coronavirus (COVID-19) and other respiratory viral diseases. In April 2020, AIM entered into the material transfer and research agreement to study the utilization of an innovative Smoore inhalation delivery device and Ampligen as a potential treatment approach for the SARS-CoV-2 pandemic.
- 05/27/2021
|
AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen
- Announces plans to conduct Phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positive Announces plans to conduct Phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positive
- 05/27/2021
|
AIM ImmunoTech Announces Positive Safety Data from the Third Cohort of Its Phase 1 Intranasal Clinical Trial
- OCALA, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events.
- 05/26/2021
|
AIM ImmunoTech CEO says the firm in ‘solid financial standing' to move forward rapidly with clinical programs
- AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Thomas Equels told investors that the immuno-pharma company rounded out the first quarter by increasing its cash reserves to “aggressively move forward” with its clinical programs. As of March 31, 2021, the Ocala, Florida-based company had cash, cash equivalents, and marketable securities of $63.6 million, compared to $54.4 million as of December 31, 2020.
- 05/18/2021
|
AIM ImmunoTech Provides First Quarter 2021 Business Update
- OCALA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021.
- 05/18/2021
|
AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo
- OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a ‘Fireside Chat' video interview with Ed Woo, Director of Research & Senior Analyst at Ascendiant Capital Markets.
- 05/03/2021
|
AIM ImmunoTech reports positive safety data in Cohort 2 of Phase 1 clinical study of Ampligen as an intranasal therapy
- AIM ImmunoTech Inc (NYSEAMERICAN:AIM) said it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability, and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events (SAE). The company, which also reported no SAEs in Cohort 1, said the study will proceed with enrollment into Cohort 3.
- 04/27/2021
|
AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases
- OCALA, Fla., April 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events (SAE). AIM also reported no SAEs in Cohort 1. The study will proceed with enrollment into Cohort 3.
- 04/27/2021
|
AIM ImmunoTech reports no serious adverse events in dosing of Cohort 1 in Phase 1 study of Ampligen drug's safety as an intranasal therapy
- AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of its Ampligen drug as an intranasal therapy and reported no serious adverse events. The company said the positive safety data paves the way for an escalation of the dose in Cohort 2 and is a critical step in its ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for coronavirus (COVID-19) and other respiratory viral diseases.
- 04/07/2021
|
AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases
- OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM's drug Ampligen as an intranasal therapy, reporting no serious adverse events, and paving the way for escalation of the dose in Cohort 2. The trial is a critical step in the company's ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.
- 04/07/2021
|
AIM ImmunoTech developing immuno-therapeutics to treat cancer and fight coronavirus
- Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of coronavirus Positive results from a pancreatic cancer Early Access Program (EAP) evaluating Ampligen in the Netherlands. What AIM ImmunoTech does: AIM ImmunoTech Inc. (NYSE:AIM) is an immuno-pharma company headquartered in Ocala, Florida which is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders.
- 03/31/2021
|
AIM ImmunoTech headed in 2021 with $54.4M in capital as it advances Ampligen to treat COVID-19 and cancer
- AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Wednesday that it ended 2020 with cash, cash equivalents, and marketable securities of $54.4 million. That's a sizable increase compared to the $8.8 million in cash it recorded as of December 31, 2019, according to a statement.
- 03/31/2021
|
AIM ImmunoTech Reports 2020 Year-End Financial Results
- OCALA, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update.
- 03/31/2021
|
AIM ImmunoTech announces addition of single-agent Ampligen arm to ongoing study of cancer patients with coronavirus
- AIM ImmunoTech Inc (NYSEAMERICAN:AIM) has announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center has approved a protocol amendment to Roswell Park's ongoing Phase 1/2a study evaluating the two-drug combination of AIM's Ampligen and interferon alpha-2b as a potential early-onset treatment for patients with cancer and mild-to-moderate coronavirus (COVID-19). AIM ImmunoTech said the IRB-approved amendment calls for randomization of an additional 20 patients.
- 03/22/2021
|
8 Biotech Penny Stocks for Investors to Watch
- Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.
- 03/10/2021
|
AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
- OCALA, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, AIM's Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC.
- 03/10/2021
|
AIM ImmunoTech doses first healthy subject in intranasal Ampligen coronavirus study
- AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Monday that it has dosed the first healthy subjects in its Phase 1 clinical study of Ampligen as a potential intranasal therapy for the coronavirus (CVOID-19) and other respiratory viral diseases. The current study plans call for the enrollment of eight healthy subjects in each of four Ampligen treatment groups and eight placebo subjects, for a total of 40 healthy subjects, the company said.
- 03/08/2021
|
AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study
- Marks important milestone towards development of Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases Marks important milestone towards development of Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases
- 03/08/2021
|
AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
- OCALA, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10, 2021.
- 03/04/2021
|
AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer
- AIM ImmunoTech Inc's (NYSE: AIM) subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission for Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer. Among other benefits, products with Orphan designation can enjoy up to ten years of protection from market competition from similar medicines with similar active components and indications.
- 02/24/2021
|
AIM ImmunoTech developing immuno-therapeutics to treat multiple types of cancers and fighting coronavirus too
- Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of coronavirus Positive results from a pancreatic cancer Early Access Program (EAP) evaluating Ampligen in the Netherlands. What AIM ImmunoTech does: AIM ImmunoTech Inc. (NYSE:AIM) is an immuno-pharma company headquartered in Ocala, Florida which is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders.
- 02/24/2021
|
AIM ImmunoTech says subsidiary wins European Commission approval of its Orphan Medicinal Product Application for Ampligen to treat pancreatic cancer
- AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Wednesday that its subsidiary NV Hemispherx Biopharma Europe has received formal notification from the European Commission approving the company's Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer. The company noted that medications designated as Orphan products by the European Medicines Agency (EMA), once commercially approved in the European Union (EU), receive benefits including up to 10 years of protection from market competition from similar medicines with similar active components and indication-for-use that are not shown to be clinically superior.
- 02/24/2021
|
AIM ImmunoTech's Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer
- OCALA, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission (EC) approving the company's Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer.
- 02/24/2021
|
7 Biotech Stocks Focused on Chronic Covid Treatment
- Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.
- 02/22/2021
|
AIM ImmunoTech receives required Ethics Committee approval in the Netherlands to commence its Phase 1 clinical study for Ampligen as an intranasal therapy
- AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) said it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of its drug Ampligen as an intranasal therapy. The company said this is a critical step in its ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for coronavirus (COVID-19) and other respiratory viral diseases.
- 02/16/2021
|
AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy
- OCALA, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM's drug Ampligen as an intranasal therapy, a critical step in the company's ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.
- 02/16/2021
|
AIM ImmunoTech To Include New Patients In Netherlands Pancreatic Cancer Program
- AIM ImmunoTech Inc (NYSE: AIM) shares are rising today after the company announced that the Netherlands regulatory authority had approved treatment for six pancreatic cancer patients as part of a new, follow-up Early Access Program (EAP). Subject to further authorization, the company plans to treat up to 16 pancreatic cancer patients with rintatolimod (Ampligen) under the EAP.
- 02/10/2021
|
AIM ImmunoTech announces expansion of its pancreatic cancer program to include new patients in the Netherlands
- AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Wednesday that the Dutch Health and Youth Care Inspectorate (IGJ) has approved use of its treatment for six pancreatic cancer patients as part of a new, follow-up Early Access Program (EAP) at Erasmus Medical Center in the Netherlands. Subject to further authorization, AIM ImmunoTech said it plans to treat up to 16 pancreatic cancer patients with rintatolimod (Ampligen) under the EAP, which follows the success of a previous multi-year Ampligen EAP for pancreatic cancer patients at Erasmus.
- 02/10/2021
|
AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands
- Early Access Program Will Also Allow Further Treatment of Patients Treated Under the Previous Ampligen Early Access Program Early Access Program Will Also Allow Further Treatment of Patients Treated Under the Previous Ampligen Early Access Program
- 02/10/2021
|
AIM ImmunoTech completes and closes ATM facility, says current capital expected to meet needs for clinical trials
- AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) said it has completed its At-The-Market (ATM) facility and close the ATM's Equity Distribution Agreement (EDA). The company, which focuses on developing therapies to treat multiple types of cancers, immune disorders, and viral diseases, including coronavirus (COVID-19), said it believes, based on its current financial condition, that it has adequate funds to meet its anticipated operational cash needs and fund its current clinical trials over approximately the next 24 months.
- 02/07/2021
|
AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials
- OCALA, Fla., Feb. 05, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed its At-The-Market (ATM) facility and closed the ATM's Equity Distribution Agreement (EDA). Management believes, based on the company's current financial condition, that it has adequate funds to meet its anticipated operational cash needs and fund current clinical trials over approximately the next twenty-four months.
- 02/05/2021
|
AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen
- AIM is Working to Develop an Effective COVID-19 Intranasal Therapy AIM is Working to Develop an Effective COVID-19 Intranasal Therapy
- 01/29/2021
|
AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET
- AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestones AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestones
- 01/15/2021
|
AIM ImmunoTech Postpones Investor Conference Call. Will Reschedule for a Later Date
- OCALA, Fla., Jan. 11, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) and its CEO Thomas K. Equels today announced that this week's planned investor conference call will be postponed and rescheduled for a later date following the death of Mr. Equels' mother over this past weekend.
- 01/11/2021
|
AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Hauler” Patient Dosed with Ampligen
- AIM to host investor conference call on January 12, 2021 at 11AM ET to discuss developments with AMP-511 trial and provide update on other major achievements and upcoming milestones AIM to host investor conference call on January 12, 2021 at 11AM ET to discuss developments with AMP-511 trial and provide update on other major achievements and upcoming milestones
- 01/06/2021
|
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers'
- Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects
- 12/24/2020
|
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers
- AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers' Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects OCALA, FL / ACCESSWIRE / December 24, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) announced today that the post-COVID-19 "Long Hauler" portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a public notification of potential patient enrollment. Eligible patients enrolled in the trial receive treatment with AIM's flagship pipeline drug Ampligen.
- 12/24/2020
|
AIM ImmunoTech Inc.'s Drug Ampligen Awarded FDA's Orphan Drug Designation Status for the Treatment of Pancreatic Cancer
- OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the U.S. Food and Drug Administration on December 17, 2020 granted Orphan Drug Designation status to AIM's drug Ampligen (rintatolimod) for the treatment of pancreatic cancer.
- 12/21/2020
|
AIM ImmunoTech Inc.'s Drug Ampligen Awarded FDA's Orphan Drug Designation Status for the Treatment of Pancreatic Cancer
- OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the U.S. Food and Drug Administration on December 17, 2020 granted Orphan Drug Designation status to AIM's drug Ampligen (rintatolimod) for the treatment of pancreatic cancer.
- 12/21/2020
|
Why These 3 Health Care Stocks Are Trading Higher Today
- AIM ImmunoTech (NYSE: AIM) shares are trading higher on Wednesday after the company dosed its first patient in a study evaluating ampligen as part of combination treatment for patients with cancer and COVID-19. AIM ImmunoTech is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases.
- 11/25/2020
|
AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19
- OCALA, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop new treatments or preventive strategies for COVID-19, the disease caused by SARS-CoV-2.
- 11/25/2020
|
AIM ImmunoTech Provides Third Quarter 2020 Business Update
- OCALA, Fla., Nov. 13, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided a business update for the third quarter ended September 30, 2020.
- 11/13/2020
|
AIM ImmunoTech Announces PLOS ONE's Publication of New Data Analyses Showing Importance of Disease Duration on Ampligen's Positive Role in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
- Early Onset Therapy May Be Key to COVID Long Hauler Syndrome Early Onset Therapy May Be Key to COVID Long Hauler Syndrome
- 11/02/2020
|
BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year
- TAMPA, Fla. and OCALA, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioFlorida has announced Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech Inc. (NYSE American: AIM), as its Weaver H. Gaines Entrepreneur of the Year. The Entrepreneur of the Year Award recognizes an entrepreneur who has made extraordinary contributions to the growth of life sciences in the leadership of a company or institution. BioFlorida represents 6,700 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors.
- 10/30/2020
|
AIM ImmunoTech (AIM) Investor Presentation - Slideshow
- The following slide deck was published by AIM ImmunoTech Inc. in conjunction with this event..
- 09/04/2020
|
We're Hopeful That AIM ImmunoTech (NYSEMKT:AIM) Will Use Its Cash Wisely
- Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- 08/17/2020
|
AIM ImmunoTech Provides Second Quarter 2020 Business Update and Reports Progress in Both COVID-19 and Cancer Trials
- Phase 1/2a trial of Ampligen in combination with interferon alfa-2b in cancer patients with COVID-19 is on track for enrollmentOCALA, FL / ACCESSWIRE / August 17, 2020 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided a business and pre-clinical/clinical update for the second quarter ended June 30, 2020.
- 08/17/2020
|
LD Micro Announces Preliminary List of Presenters for the LD 500
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
49 Public Companies to Present at the SNN Network Virtual Conference on August 3-6, 2020
- LOS ANGELES, CA / ACCESSWIRE / August 3, 2020 / The SNN Network Virtual Conference will take place on August 3rd \\- 6th, 2020, where 49 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.
- 08/03/2020
|
AIM ImmunoTech to Present at the SNN Network Virtual Investor Conference on Monday, August 3rd
- OCALA, FL / ACCESSWIRE / July 27, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it will be presenting at the SNN Network Virtual Investor Conference on Monday, August 3, 2020 at 1:30 PM EST.
- 07/27/2020
|
AIM ImmunoTech Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center Supporting Phase 1/2 Clinical Trial of Ampligen Combined with Interferon Alfa-2b in COVID-19 Patients with Cancer
- OCALA, FL / ACCESSWIRE / July 9, 2020 / AIM ImmunoTech (NYSE AMERICAN:AIM), today announced that it has entered into a clinical trial agreement (CTA) with Roswell Park Comprehensive Cancer Center to support Roswell Park's Phase 1/2a trial of Ampligen (rintatolimod) in combination with interferon alfa-2b, in cancer patients with COVID-19, the disease caused by the SARS-CoV-2 coronavirus. Funding for the clinical trial is provided, in part, through grants from the National Cancer Institute and AIM, as well as institutional support from Roswell Park.
- 07/09/2020
|
AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, to Test Ampligen as Potential Vaccine Adjuvant for COVID-19
- OCALA, FL / ACCESSWIRE / July 6, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that is has signed a material transfer and research agreement with Japan's National Institute of Infectious Diseases (NIID) and Shionogi & Co., Ltd. (Shionogi), a leading global pharmaceutical company headquartered in Japan, in order to test AIM's drug Ampligen as a potential adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The details of all preclinical and clinical results will remain confidential until released by NIID and Shionogi.
- 07/06/2020
|
AIM ImmunoTech Added to Russell Microcap(R) Index
- OCALA, FL / ACCESSWIRE / June 29, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it has been added to the Russell Microcap® Index, following the annual Russell indexes reconstitution, ...
- 06/29/2020
|
Hemispherx BioPharma (NYSEAMERICAN:HEB) Share Price Crosses Above 200 Day Moving Average of $0.00
- Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.00 and traded as high as $2.36. Hemispherx BioPharma shares last traded at $2.27, with a volume of 2,591,446 shares traded. Hemispherx BioPharma Company Profile (NYSEAMERICAN:HEB) Hemispherx Biopharma, […]
- 06/26/2020
|
AIM ImmunoTech Provides Update on Commercial Launch of Ampligen(R) in Argentina for the Treatment of Chronic Fatigue Syndrome | | IT Business Net
- Receives clearance from Argentina's FDA to import first shipment of Ampligen® for commercial sale in Argentina AIM 'sets sights' on treating COVID-19 induced chronic fatigue in Argentin
- 06/15/2020
|
AIM ImmunoTech Provides Update on Commercial Launch of Ampligen(R) in Argentina for the Treatment of Chronic Fatigue Syndrome
- OCALA, FL / ACCESSWIRE / June 15, 2020 / AIM ImmunoTech (NYSE American:AIM), today provided an update on the commercial launch of Ampligen® for the treatment of severe Chronic Fatigue Syndrome (CFS) in Argentina. Ampligen®, the first drug ever to receive commercial approval in any country as a treatment for severe ME/CFS, has achieved its next important regulatory step having received import clearance from Argentina's Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT), Argentina's equivalent to the FDA, to import the first shipment of commercial grade vials of Ampligen® to Argentina.
- 06/15/2020
|
AIM ImmunoTech Files Provisional Patent Application for the Use of Ampligen(R) as a Potential Therapy for COVID-19 Induced Chronic Fatigue
- OCALA, FL / ACCESSWIRE / June 11, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it has filed a provisional patent application for, among other discoveries, the use of its experimental drug Ampligen® as a potential early-onset therapy for the treatment of COVID-19 induced chronic fatigue, which shows similarities to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Ampligen®, approved in Argentina, is late-stage in the experimental development pipeline in the U.S. While there is ongoing and planned research by the U.S. Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH) and other groups to study chronic fatigue in post-COVID-19 patients, the Company believes Ampligen may play an important role in addressing this multi-faceted disease.
- 06/11/2020
|
COVID-19 Drug and Vaccine Pipeline Status Report - Research; Pre-Clinical; Phase 1, 2 & 3 Drug Candidates - ResearchAndMarkets.com
|
Skegness holiday parks could stay open longer after devastating virus impact
- It's estimated that 90 percent of staff in the sector have been furloughed
- 05/24/2020
|
Holiday park plan revealed after shock impact of virus on coast emerges
- The season looks set to be scrapped
- 05/19/2020
|
Call for planned new cinema to move for velodrome and cycling museum
- Cycling campaigners want to change the layout of the Firepool development site in Taunton
- 05/18/2020
|
AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer; Provides Corporate Business Update for the First Quarter of 2020
- OCALA, FL / ACCESSWIRE / May 14, 2020 / AIM ImmunoTech (NYSE American:AIM) today announced that the U.S. Food and Drug Administration has authorized the first human trial assessing the safety and effectiveness of the Company's lead asset, Ampligen (rintatolimod), in combination with interferon alfa-2b, in cancer patients with COVID-19, the disease caused by the SARS-CoV-2 coronavirus. The Company also provided a corporate business update and reported financial results for the first quarter ended March 31, 2020. The new clinical trial, to be conducted at Roswell Park Comprehensive Cancer Center under the leadership of Pawel Kalinski, MD, PhD, a pioneer in developing this combination as an investigational treatment for cancer, and Brahm Segal, MD, will test the safety of this combination regimen in patients with cancer and mild to moderate COVID-19, and the extent to which this therapy will promote clearance of the SARS-CoV-2 virus from the upper airway.
- 05/14/2020
|
What does COVID-19 do to the body?
- "Three weeks in hell" or a bad cold? What does COVID-19 feel like, and how does your body fight back?
- 05/07/2020
|
Stocks To Watch: Jobs Report, Virtual Conferences And Blue Chips On Tap
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 05/02/2020
|
AIM ImmunoTech’s CEO to Present at Maxim’s Infectious Disease Virtual Conference
- OCALA, FL / ACCESSWIRE / April 29, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that CEO Thomas K. Equels is scheduled to present
- 04/29/2020
|
BBBY, DVAX among premarket gainers
- Broadwind Energy (NASDAQ:BWEN) +60%. on $19M order.TrovaGene (NASDAQ:TROV) +44% on new positive results from its ongoing Phase 1b/2 clinical trial of onvansertib in combination with FOLFIRI and Avasti
- 04/28/2020
|
Facebook Takes Aim At Zoom With Video Chat Upgrade
- Facebook takes aim at Zoom with video chat upgrade
- 04/24/2020
|
AIM ImmunoTech’s CEO to Present at the Planet Microcap Showcase Virtual Investor Conference 2020
- OCALA, FL / ACCESSWIRE / April 20, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that Chief Executive Officer, Thomas K. Equels is scheduled to present at the Planet Microcap Showcase 2020 on Wednesday, April 22 at 10:40 AM Eastern Time. Mr. Equels will be hosting the presentation and answering questions from investors.
- 04/20/2020
|
Cadila Healthcare at the forefront, looks at biologic drug to treat Covid
- Company is already working on developing 2 vaccine candidates, diagnostic kits and also making HCQ
- 04/20/2020
|
Head to Head Comparison: BioCryst Pharmaceuticals (NASDAQ:BCRX) vs. AIM ImmunoTech (NASDAQ:AIM)
- BioCryst Pharmaceuticals (NASDAQ:BCRX) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations. Profitability This table compares BioCryst Pharmaceuticals and AIM ImmunoTech’s net margins, return on equity and […]
- 04/12/2020
|
AIM Stock Is a Moonshot That Lacks the Fuel
- Despite a relevant search for a coronavirus treatment, AIM ImmunoTech faces steep competition and questions regarding credibility.
- 04/09/2020
|
Ignore the Coronavirus Catalyst for ABBV Stock
- AbbVie servers patients with serious conditions and these are exactly the people who are most at risk during this pandemic.
- 04/08/2020
|
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) * Forty Seven Inc (NASDAQ: FTSV) * Masimo Corporation (NASDAQ: MASI) * Seattle Genetics, Inc. (NASDAQ: SGEN) * Vertex Pharmaceuticals Incorporated
- 04/07/2020
|
AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic
- OCALA, FL / ACCESSWIRE / April 6, 2020 / AIM ImmunoTech (NYSE American:AIM) today announced it has entered into a Material Transfer and Research Agreement (MTA) with Shenzhen Smoore Technology Limited. According to a market survey report by Frost & Sullivan, Smoore is the world's largest vaping device manufacturer in terms of revenue in 2019, whose products include but are not limited to high-tech inhalation devices. The purpose of the MTA is to research in China the efficacy of Smoore's inhalation delivery device using Ampligen, AIM's flagship drug, which has been approved for ME/CFS in Argentina and experimental through phase 3 clinical trials in the U.S. AIM believes Ampligen has potential as a prophylactic/early-onset therapeutic against COVID-19, the disease caused by SARS-CoV-2.
- 04/06/2020
|
AIM ImmunoTech Announces the National Cancer Institute’s Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers
- OCALA, FL / ACCESSWIRE / April 6, 2020 / The National Cancer Institute issued an award of $14.54 million to Roswell Park Comprehensive Cancer Center to test chemokine modulation incorporating AIM ImmunoTech's Ampligen as an immuno-modulator as part of a strategy to turn ‘cold' tumors into ‘hot' tumors. Chemokine modulation is designed to enhance the effectiveness of common immunotherapies and lead to new, life-saving combination therapies for people battling cancer. The multi-center team will be led by Pawel Kalinski, MD, PhD of Roswell Park, in collaboration with partners at University of Pittsburgh Medical Center (UPMC) and The Tisch Cancer Institute at Mount Sinai.
- 04/06/2020
|
Don’t Pull the Trigger on AIM ImmunoTech Stock
- If it sounds too good to be true, it probably is. And that's likely the case when you look deeper into what's going on with AIM stock.
- 04/02/2020
|
AIM Stock: You’ve Got a Better Shot of Getting Rich Buying a Lottery Ticket
- AIM ImmunoTech reported its 2019 results on March 31. Despite the coronavirus push, AIM stock headed lower on the news.
- 04/02/2020
|
HAL, APA among premarket gainers
- SG Blocks (NASDAQ:SGBX) +100% on Q4 results.EyeGate Pharmaceuticals (NASDAQ:EYEG) +51% on positive dry eye data.Kiniksa Pharmaceuticals (NASDAQ:KNSA) +39% as mavrilimumab shows treatment response in C
- 03/31/2020
|
AIM ImmunoTech Reports 2019 Year-end Financial Results
- OCALA, FL / ACCESSWIRE / March 31, 2020 / AIM ImmunoTech (NYSE American:AIM) announces financial results for the fiscal year ended December 31, 2019, and provides a business update. Research and development expenses for 2019 were $4.651 million, compared with $4.778 million for 2018. Since the outbreak of SARS-CoV-2 - which causes the disease COVID-19 - AIM has been actively engaged in determining whether its drug Ampligen could be an effective treatment for this virus.
- 03/31/2020
|
55 Stocks Moving In Monday's Mid-Day Session
- Gainers
SuperCom Ltd. (NASDAQ: SPCB) shares climbed 202% to $1.48 after the company announced it has shipped Coronavirus quarantine compliance technology for an immediate pilot....
- 03/30/2020
|
ABT, DD among premarket gainers
- Plus Therapeutics. (NASDAQ:PSTV) +63% in-licenses novel oncology candidates.Bellerophon Therapeutics (NASDAQ:BLPH) +40% as first COVID-19 patient has been treated with the INOpulse inhaled nitric oxid
- 03/30/2020
|
In the Coronavirus Vaccine Race, AIM Stock Isn’t a Likely Winner
- AIM stock was a big winner on hopes it could join the response to the coronavirus. But its history suggests those hopes are too optimistic.
- 03/27/2020
|
NRZ, TLRY among premarket gainers
- Granite Point Mortgage Trust (NYSE:GPMT) +104% on suspending Q1 dividend in move to conserve cash.MFA Financial (NYSE:MFA) +75% on cancelling dividend.Wanda Sports Group Company (NASDAQ:WSG) +55% afte
- 03/26/2020
|
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic
- OCALA, FL / ACCESSWIRE / March 26, 2020 / AIM ImmunoTech (NYSE American:AIM) today announced that it is actively seeking investigators and sites for clinical testing of Ampligen as a protective prophylaxis and an early-onset treatment for COVID-19, the disease caused by the SARS-CoV-2 coronavirus. The company is targeting the United States, Europe, Asia and Argentina for its clinical trials and, as necessary steps before clinical trials could begin, the company is in the process of soliciting one or more sites and qualified principal investigators in one or more countries. Protocols for potential clinical trial are in the final stages of development.
- 03/26/2020
|
SLS, APRN among premarket gainers
- Biomerica (NASDAQ:BMRA) +133% on advancement of rapid coronavirus test.IMV (NASDAQ:IMV) +55% on coronavirus vaccine plan.Vaxart (NASDAQ:VXRT) +46% on coronavirus vaccine deal.Blue Apron Holdings (NYSE
- 03/18/2020
|
Analyzing Editas Medicine (NASDAQ:EDIT) & AIM ImmunoTech (NASDAQ:AIM)
- AIM ImmunoTech (NYSE:AIM) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation. Earnings and Valuation This table compares AIM ImmunoTech and Editas Medicine’s top-line revenue, earnings per […]
- 03/18/2020
|
The Coronavirus Pandemic Has Revealed Some Micro-Cap Opportunities
- The Coronavirus Pandemic Has Revealed Some Micro-Cap Opportunities, Stocks: CODX,HOLX,AIM,NNVC,GOOG,GOOGL,FB,LAKE,TBLT,LOW,HD,, release date:Mar 13, 2020
- 03/13/2020
|
INO, MNK among premarket gainers
- Predictive Oncology (NASDAQ:POAI) +50% on launching a new AI platform for vaccine and drug development targeting coronaviruses and acute respiratory syndromes.Chembio Diagnostics (NASDAQ:CEMI) +42% on
- 03/12/2020
|
Mid-Afternoon Market Update: Dow Tumbles 8%; AIM ImmunoTech Shares Spikes Higher
- Toward the end of trading Monday, the Dow traded down 8% to 23794.55 while the NASDAQ fell 6.95% to 7,979.78. The S&P also fell, dropping 7.71% to 2,743.27. Coronavirus cases...
- 03/09/2020
|
Mid-Day Market Update: Dow Falls 1400 Points; Matador Resources Shares Plunge
- Midway through trading Monday, the Dow traded down 5.43% to 24,461 while the NASDAQ fell 4.35% to 8,202.44. The S&P also fell, dropping 5.03% to 2822.74. Coronavirus cases...
- 03/09/2020
|
101 Stocks Moving In Monday's Mid-Day Session
- Gainers
Spherix Incorporated (NASDAQ: SPEX) shares jumped 139% to $3.92 after jumping 131% on Friday.
AIM ImmunoTech Inc. (NYSE: AIM) shares jumped 63.1% to $3.43 amid the...
- 03/09/2020
|
AIM ImmunoTech’s Drug Ampligen to Be Tested by Japan’s National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19
- OCALA, FL / ACCESSWIRE / March 9, 2020 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the National Institute of Infectious Diseases (NIID) in Japan will begin testing AIM's drug Ampligen as a potential treatment for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The experimental program will be conducted at both the NIID and the University of Tokyo.
- 03/09/2020
|
Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April
- Shares of Inovio Pharmaceuticals Inc. rallied more than 16% Tuesday, after the company said it’s accelerating the timeline for development of a vaccine to...
- 03/08/2020
|
MRVL, VIPS among premarket gainers
- Cohen & Company (NYSEMKT:COHN) +105% on Q4 results.Can-Fite BioPharma (NYSEMKT:CANF) +42% on collaboration to evaluate Piclidenoson for the potential treatment of coronavirus infection.iBio (NYSEM
- 03/05/2020
|
92 Biggest Movers From Yesterday
- Gainers
Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 45% to close at $3.03 on Wednesday. Cellect Biotechnology and Canndoc Ltd. agreed to enter into strategic pharma...
- 03/05/2020
|
UnitedHealth stock leads health-care stock rally after Biden’s Super Tuesday victory
- A strong showing by Democratic presidential candidate Joe Biden on Super Tuesday sparked a broad-based rally in health-care stocks Wednesday, sending United...
- 03/04/2020
|
CVS, UNH among premarket gainers
- Cellect Biotechnology (NASDAQ:APOP) +38% on Canndoc deal.Dynatronics (NASDAQ:DYNT) +28%.AIM ImmunoTech (NYSEMKT:AIM) +24% on recent announcements on Covid-19 front.Arcturus Therapeutics Holdings (NASD
- 03/04/2020
|
And the Covid-19 list keeps growing...
- Recent announcements on the COVID-19 front:Luminex (NASDAQ:LMNX): Working on two SARS-Cov-2 tests: NxTAG CoV Expanded Panel: should be available to ship to customers in a few weeks. Testing in China t
- 03/04/2020
|
Healthcare dominates premarket losers amidst coronavirus situation
- Spherix (NASDAQ:SPEX) -25%.Dynatronics (NASDAQ:DYNT) -22%.China Pharma Holdings (NYSEMKT:CPHI) -19%.Co-Diagnostics (NASDAQ:CODX) -17%.Tilray (NASDAQ:TLRY) -14% on Q4 earnings.Cleveland BioLabs (NASDAQ
- 03/03/2020
|
NVAX, SGMO among premarket gainers
- Dynatronics (NASDAQ:DYNT) +224%.Altimmune (NASDAQ:ALT) +143% on completing first development milestone toward a single-dose intranasal COVID-19 vaccine.Allied Healthcare Products (NASDAQ:AHPI) +103% a
- 02/28/2020
|
WLL, SPEX, CODX and AIM among midday movers
- Gainers: iBio (NYSEMKT:IBIO) +131%.GAIN Capital Holdings (NYSE:GCAP) +66%.Vaxart (NASDAQ:VXRT) +57%.Co-Diagnostics (NASDAQ:CODX) +55%.Vir Biotechnology (NASDAQ:VIR) +51%.Allied Healthcare Products (NA
- 02/27/2020
|
NVAX, INO among premarket gainers
- Allied Healthcare Products (NASDAQ:AHPI) +71%.GAIN Capital Holdings (NYSE:GCAP) +66% on Q4 results.Co-Diagnostics (NASDAQ:CODX) +66%.Alpha Pro Tech (NYSEMKT:APT) +48% after updating on orders.AIM Immu
- 02/27/2020
|
AIM ImmunoTech Joins with ChinaGoAbroad for an Ampligen China Entry Against COVID-19, the New SARS-like Coronavirus Disease Epidemic
- OCALA, FL / ACCESSWIRE / February 27, 2020 / AIM ImmunoTech (NYSE American: AIM, or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the Company has joined with ChinaGoAbroad (CGA) to facilitate the entry of AIM's experimental drug Ampligen into the People's Republic of China (PRC) for use as a prophylactic/early-onset therapeutic against COVID-19, the new SARS-like coronavirus infection that has reached epidemic proportions. CGA is a member-based online information platform and offline advisory firm serving to facilitate two-way international transactions relating to the PRC in close collaboration with the China Overseas Development Association (CODA), which had up until recently reported to the PRC National Development and Reform Commission (NDRC), which in turn reports to the State Council (China's cabinet).
- 02/27/2020
|
TSLA, KR among premarket gainers
- Bellerophon Therapeutics (NASDAQ:BLPH) +67% on positive top-line data from a recently completed acute, intra-patient, dose escalation, hemodynamics study of INOpulse for the treatment of Pulmonary Hyp
- 02/18/2020
|
AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic
- OCALA, FL / ACCESSWIRE / February 18, 2020 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided its stockholders with an update on its efforts to develop Ampligen as a protective therapeutic and a vaccine in the new coronavirus epidemic. Ampligen, the company's flagship drug, has a commercial approval in Argentina, early-access therapeutic approval in the Netherlands, and is in numerous FDA-authorized clinical trials in the United States. This letter provides a detailed scientific basis for why the company is moving forward in the important and volatile Wuhan coronavirus space.
- 02/18/2020
|
INO, CRSP among premarket gainers
- CounterPath (NASDAQ:CPAH) +49% on securing five-year deal with Vodafone Fiji to extend superior quality voice services to consumers.Alpha Pro Tech (NYSEMKT:APT) +29% as orders surge for Alpha Pro Tech
- 02/13/2020
|
AIM ImmunoTech’s CEO to Appear Live Today on FOX Business Network’s The Claman Countdown and Cheddar’s Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus
- OCALA, FL / ACCESSWIRE / February 12, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that its Chief Executive Officer, Thomas K. Equels, will appear live today as a guest on FOX Business Network's The Claman Coutdown and Cheddar's Opening Bell. Mr. Equels is scheduled to appear on Cheddar's Opening Bell with hosts Hope King and Nora Ali at 10:20 AM ET.
- 02/12/2020
|
94 Biggest Movers From Yesterday
- Gainers
Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) shares gained 78.5% to close at $3.66 after the company announced a license agreement with Zhejiang HaiChang Biotechnology....
- 02/12/2020
|
AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen® for Use Against the SARS-like Wuhan 2019 Novel Coronavirus
- AIM ImmunoTech Inc. (NYSE American: AIM) today announced the filing of three provisional patent applications related to its drug candidate Ampligen in the company’s efforts toward joining the global health community in the fight against the deadly Wuhan coronavirus that has so far infected approximately 40,000 people and killed almost one thousand, primarily in China. After a 2002 SARS outbreak in the Guangdong province of southern China caused more than 8,000 cases and more than 800 deaths, the United States’ National Institutes of Health contracted studies to evaluate potential treatments for SARS.
- 02/11/2020
|
AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus
- OCALA, FL / ACCESSWIRE / February 11, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announced the filing of three provisional patent applications related to its drug candidate Ampligen in the company's efforts toward joining the global health community in the fight against the deadly Wuhan coronavirus that has so far infected approximately 40,000 people and killed almost one thousand, primarily in China. After a 2002 SARS outbreak in the Guangdong province of southern China caused more than 8,000 cases and more than 800 deaths, the United States' National Institutes of Health contracted studies to evaluate potential treatments for SARS.
- 02/11/2020
|
AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies
- OCALA, FL / ACCESSWIRE / February 5, 2020 / AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced posting by the University of Pittsburgh Medical Center (UPMC) on January 28, 2020 via ClinicalTrials.gov of completion of an independent, third-party clinical trial to evaluate the safety and activity of a triple combination (chemokine modulatory regimen or CKM) of celecoxib, interferon alfa (IFN), and Ampligen (rintatolimod), given with a dendritic cell (DC) vaccine, as a potential treatment for metastatic peritoneal surface malignancies after standard of care surgery. The principal investigator of the trial was David L. Bartlett, MD, an internationally recognized cancer researcher at UPMC, in collaboration with the National Cancer Institute.
- 02/05/2020
|
SDRL, FCEL among premarket gainers
- Ocean Bio-Chem (NASDAQ:OBCI) +80% as its subsidiary Star brite announces registered EPA product kills the Coronavirus.Happiness Biotech Group (NASDAQ:HAPP) +70% on sales of Cordyceps Mycelia products
- 01/28/2020
|
Reviewing Autolus Therapeutics (NASDAQ:AUTL) & AIM ImmunoTech (NASDAQ:AIM)
- Autolus Therapeutics (NASDAQ:AUTL) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk. Analyst Ratings This is a breakdown of recent ratings and recommmendations for Autolus Therapeutics and […]
- 01/25/2020
|
Read This Before Selling AIM ImmunoTech Inc. (NYSEMKT:AIM) Shares
- We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- 01/16/2020
|
AIM ImmunoTech to Present at the Investor Summit in Philadelphia
- OCALA, FL / ACCESSWIRE / December 11, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, ...
- 12/11/2019
|
AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020
- OCALA, FL / ACCESSWIRE / December 4, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as severe chronic fatigue syndrome (CFS) - today provided its stockholders with an update on the first three quarters of 2019 and detailed expected upcoming milestones in clinical studies using its drug Ampligen. This has been a transformational year for AIM ImmunoTech. Several more clinical trials are slated for 2020.
- 12/04/2019
|
CORRECTION: AIM ImmunoTech Provides Business Update for the Third Quarter of 2019
- The company had cash, cash equivalents and marketable securities of $1,825,000 as of December 31, 2018, not December 31, 2019. OCALA, FL / ACCESSWIRE / November 15, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as severe chronic fatigue syndrome (CFS) - provides a business update for the third quarter ended September 30, 2019, and has filed its form 10-Q with the U.S. Securities and Exchange Commission, which is available on the Company's website. Announced the U.S. Department of Defense's (DOD) $6.42M "Breakthrough Award" to Roswell Park Comprehensive Cancer Center to fund a clinical trial to study Ampligen as a potential synergistic agent in combination with several other immunotherapies, such as pembrolizumab, in the treatment of brain-metastatic breast cancer.
- 11/15/2019
|
AIM ImmunoTech Provides Business Update for the Third Quarter of 2019
- OCALA, FL / ACCESSWIRE / November 15, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as severe chronic fatigue syndrome (CFS) - provides a business update for the third quarter ended September 30, 2019, and has filed its form 10-Q with the U.S. Securities and Exchange Commission, which is available on the Company's website. Announced the U.S. Department of Defense's (DOD) $6.42M "Breakthrough Award" to Roswell Park Comprehensive Cancer Center to fund a clinical trial to study Ampligen as a potential synergistic agent in combination with several other immunotherapies, such as pembrolizumab, in the treatment of brain-metastatic breast cancer.
- 11/15/2019
|
AIM ImmunoTech to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
- OCALA, FL / ACCESSWIRE / October 23, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, ...
- 10/23/2019
|
Fatigue: Why Am I So Tired?
- Fatigue, also referred to as tiredness, exhaustion, lethargy, and listlessness, describes a physical and/or mental state of being tired and weak. Although physical and mental fatigue are different,…
- 04/10/2017
|
